雌激素受体GPR30在上皮性卵巢癌中的表达及其与MMP-9表达的相关性  

The expression of a novel estrogen receptor,GPR30,in epithelial ovarian carcinoma and its correlation with MMP-9

作　　者：刘慧迪[1] 闫彦[1] 曹雪峰[1] 谭培珠[1] 温海霞[1] 吕春梅[1] 李晓梅[2] 刘国艺[2] 

机构地区：[1]哈尔滨医科大学生理学教研室,哈尔滨150081 [2]哈尔滨医科大学附属第三医院病理科,哈尔滨150040

出　　处：《生理学报》2010年第6期524-528,共5页Acta Physiologica Sinica

基　　金：supported by the Natural Science Foundation of Heilongjiang Province,China(No.D201008);Postdoctoral Grant of Heilongjiang Province,China

摘　　要：本文旨在研究新型雌激素受体——G蛋白耦联受体30(G protein-coupled receptor30,GPR30)在上皮性卵巢癌中的表达,及其与基质金属蛋白酶9(matrix metalloproteinases-9,MMP-9)表达的相关性。收集39例上皮性卵巢肿瘤组织标本,包括上皮性卵巢癌30例(浆液性囊腺癌19例、粘液性囊腺癌5例和子宫内膜样癌6例)、良性上皮性卵巢肿瘤9例,并取4例正常卵巢组织进行对照,应用免疫组织化学法检测GPR30和MMP-9的表达,使用?2检验、Fisher’s精确检验和Spearman等级相关分析等统计学方法对所得数据进行统计分析。结果显示,上皮性卵巢癌中GPR30的高表达率显著高于良性卵巢肿瘤(P<0.01)和正常卵巢组织(P<0.05);上皮性卵巢癌中MMP-9的高表达率显著高于正常卵巢组织(P<0.05),但与良性卵巢肿瘤无明显差异。肿瘤病理类型、分期和患者年龄因素与GPR30高表达率的相关性分析显示:不同病理类型上皮性卵巢癌的GPR30高表达率之间存在显著性差异(P<0.05),而各病理类型的MMP-9高表达率之间没有差异;临床III^IV期上皮性卵巢癌的GPR30高表达率显著高于I^II期(P<0.05),二者MMP-9高表达率之间没有差异;三个年龄组病例中的GPR30高表达率之间未见明显差异,三者MMP-9高表达率之间亦没有差异。Spearman等级相关分析显示上皮性卵巢癌组织中GPR30与MMP-9的表达之间具有正向相关性(P<0.01)。以上结果提示,GPR30可能参与上皮性卵巢癌的发生发展,并与其侵袭和转移具有一定的相关性,可作为卵巢癌早期诊断和恶性程度判断的指标之一。The aim of the present study is to investigate the expression of a novel estrogen receptor,G protein-coupled receptor 30（GPR30） and its correlation with matrix metalloproteinases-9（MMP-9） in epithelial ovarian cancer（EOC）.Ovary tissues were obtained from 39 female patients,including 30 cases of EOC and 9 cases of benign ovarian tumor.Four normal ovary tissues were used as control.Immunohistochemical staining was used to detect the expressions of GPR30 and MMP-9.Chi square test,Fisher＇s exact test and Spearman＇s rank correlation analysis were used for statistical analysis.The results showed that GPR30 overexpression rate in EOC cases was significantly higher than those in benign ovarian tumor and normal ovary cases.Whereas MMP-9 overexpression rate in EOC cases was significantly higher than that in normal ovary cases,without any difference to that in benign ovarian tumor cases.To demonstrate the relationship between GPR30 and clinicopathological variables of EOC,we further analyzed the pathology type,FIGO stage and age of patients sampled in our study.The analysis showed there were significant differences of GPR30 overexpression rate among various pathology types and different FIGO stages（P0.05）,and no significant difference of both GPR30 and MMP-9 among three age groups（P0.05）.Moreover,GPR30 expression was positively correlated with MMP-9（rs=1.000,P=0.002）.These results suggest that GPR30 may be involved in the invasion and metastasis of EOC,being a potential index of EOC early diagnosis and malignancy grade prediction.

关 键 词：上皮性卵巢癌 G蛋白耦联受体30 基质金属蛋白酶9 

分 类 号：R737.31[医药卫生—肿瘤]